Investigating biomarkers of Staphylococcus aureus bacteremia in patients - School of Pharmacy

The Centers for Disease Control identifies methicillin-resistant S. aureus (MRSA) as a serious health threat with greater than 100,000 invasive infections and 20,000 patient deaths annually in the United States. Despite recent advancements in available treatment options for methicillin-sensitive S.

Frontiers Management of Staphylococcus aureus Bloodstream Infections

Bloodstream infections in critically ill patients: an expert statement

B.I.G. Summer 2023 – Institute for Quantitative and Computational Biosciences

Mechanism and pharmacodynamics of glyco/lipopeptide synergy with older antimicrobials - School of Pharmacy

Exploration of sepsis assisting parameters in hospital autopsied-patients: a prospective study

Therapy of Staphylococcus aureus bacteremia: Evidences and challenges Enfermedades Infecciosas y Microbiología Clínica (English Edition)

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice, Journal of Nanobiotechnology

Infectious Disease Special Edition - Summer 2021 by McMahon Group - Issuu

Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? - Abstract - Europe PMC

Reducing the risk of bacteremia